Xetra
Every company in the roster listed on Xetra.
Every company in the roster listed on Xetra.
5 of 5 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
BayerBAYN · Xetra | 21 assets: 12 approved, 3 Ph 3, 3 Ph 2, 1 Ph 1, 2 other | MiglitolUS approval withdrawn · Type 2 DiabetesPartial signal | Dec 2026Mosliciguat · Phase 2 | — | $6.6BMar 2026 | Ended Aug 2026 | ~$6.6B |
Formycon AGFYB · Xetra | 3 assets: 3 approved | Approved assets only | None on record | — | $81MDec 2025 | — | — |
Fresenius Medical Care AGFME · Xetra | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Fresenius SE & Co. KGaAFRE · Xetra | 2 assets: 2 approved | Approved assets only | None on record | — | $5.0BJun 2026 | Profitable | ~$770M |
Heidelberg Pharma AGHPHA · Xetra | 1 asset: 1 Ph 2 | Pamlectabart tismanitinPhase 1/2 · Multiple Myeloma | Mar 2028Pamlectabart tismanitin · Phase 1/2 | — | $38MMay 2025 | Ended Oct 2026 | ~$29M |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.